Dual-therapy CD34 antibody-covered sirolimus-eluting COMBO stents versus sirolimus-eluting Orsiro stents in percutaneous coronary intervention: five-year outcomes of the SORT OUT X randomised clinical trial

Lars Jakobsen¹, MD, PhD; Evald H. Christiansen¹, MD, PhD; Trine Frøslev², MSc; Bent Raungaard³, MD, PhD; Jens Flensted Lassen⁴, MD, PhD; Ashkan Eftekhari³, MD, PhD; Lisette O. Jensen⁴, MD, PhD, DMSci

Contemporary drug-eluting stents (DES) have significantly reduced target lesion failure (TLF) rates after percutaneous coronary intervention (PCI), yet challenges remain. The dual-therapy sirolimus-eluting and CD34 antibody-coated COMBO stent (DTS; OrbusNeich) was designed to enhance early healing1. In the SORT OUT X trial, the sirolimus-eluting Orsiro stent (SES; Biotronik) was found to be superior to the DTS after 12 months, mainly because the DTS was associated with an increased risk of target lesion revascularisation (TLR)2. At 3 years, the SES was still superior to the DTS, mainly because the DTS was associated with an increased risk of target lesion failure within the first year but not from 1 to 3 years3. Lately, the DTS was found to be non-inferior to the biolimus A9-eluting BioMatrix Alpha stent (Biosensors International)4. In general, collecting long-term data is pivotal for understanding the behaviour of certain technologies over time. Furthermore, the DTS has been reported to show a unique late neointimal regression that has not been reported for any other DES5. The present study extends the SORT OUT X follow-up to...